MYGN Stock Might Gain From SneakPeek Availability in Retail Stores
Myriad Genetics announces the availability of SneakPeek - the first at-home early fetal sex test in Walmart, Walgreens and CVS…
15,209$
-3,01%
Echtzeit-Aktienkurs Myriad Genetics Inc.
Bid:
Ask:
Nachrichten zur Myriad Genetics Inc. Aktie
Myriad Genetics, Inc. (MYGN) Q3 2024 Earnings Call Transcript
…
MYGN Beats on Q3 Earnings and Revenues, Raises 24 EPS View
Myriad Genetics delivers strong third-quarter results, driven by growth within Pharmacogenomics and Prenatal. The company increases its full-year EPS guidance.…
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
Myriad Genetics comments on UnitedHealthcare’s updated medical policy for pharmacogenetic testing…
Should You Continue to Retain MYGN Stock in Your Portfolio?
Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors sentiment.…
Global Gene Panel Market Size To Worth USD 4.46 Billion by 2033 | CAGR of 13.75%
The Global Gene Panel Market Size was Valued at USD 1.23 Billion in 2023 and the Worldwide Gene Panel Market…
Global Cancer Biomarkers Market to Surge from USD 22.78 Billion in 2023 to USD 82.66 Billion by 2033, Achieving a CAGR of 13.76%
According to a research report published by Exactitude Consultancy, Companies covered:Abbott Laboratories Inc. - North America, Agilent Technologies Inc. -…
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic…
Myriad Genetics, Inc. (MYGN) Q2 2024 Earnings Call Transcript
…
Myriad Genetics (MYGN) Q2 Earnings Surpass, 24 Outlook Raised
Myriad Genetics (MYGN) delivers a strong performance across its portfolio in the second quarter of 2024 and increases its long-term…
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease.…
Myriad Genetics (MYGN) Advances in MRD Space With New Patent
Myriad Genetics (MYGN) achieves a second foundational patent bolstering the MRD assay development.…
Global PCOS Diagnostic Market Size To Exceed USD 6.1 Billion By 2033 | CAGR Of 5.18%
The Global PCOS Diagnostic Market Size was Valued at USD 3.68 Billion in 2023 and the Worldwide PCOS Diagnostic Market…
Global Companion Diagnostics Market Size To Exceed USD 23.12 Billion By 2033 | CAGR Of 12.50%
The Global Companion Diagnostics Market Size was Valued at USD 7.12 Billion in 2023 and the Worldwide Companion Diagnostics Market…
Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing
Myriad Genetics (MYGN) collaborates with GSK to improve access to HRD diagnostic testing for HGSOC patients.…
Myriad Genetics (MYGN) Banks on Innovation Amid Macro Woes
Myriad Genetics (MYGN) continues to enhance its customer targeting, digital marketing and overall operating model to drive commercial leverage in…
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
VENLO, The Netherlands and SALT LAKE CITY, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime…
GNW-Adhoc: QIAGEN und Myriad Genetics entwickeln vermarktbaren HRD-Test für weltweite Forschung und Begleitdiagnostik
^Next-Generation-Sequencing-Test für homologe Rekombinationsdefizienz (HRD)basierend auf QIAGENs QIAseq-xHYB-Technologie, QIAGEN Digital Insight Lösungenund…
QIAGEN N.V.: QIAGEN und Myriad Genetics entwickeln vermarktbaren HRD-Test für weltweite Forschung und Begleitdiagnostik
Next-Generation-Sequencing-Test für homologe Rekombinationsdefizienz (HRD) basierend auf QIAGENs QIAseq-xHYB-Technologie, QIAGEN Digital Insight Lösungen und proprietären, von der FDA zugelassenen ...…
Myriad Genetics, Inc. (MYGN) Q1 2024 Earnings Call Transcript
…
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1
Myriad Genetics (MYGN) first-quarter average revenue per test across its product portfolio benefited from expanded coverage and ongoing efforts in…
Global Theranostics Market Size To Worth USD 3.3 Billion By 2033 | CAGR of 5.68%
The Global Theranostics Market Size was Valued at USD 1.9 Billion in 2023 and the Worldwide Theranostics Market Size is…
Myriad Genetics (MYGN) Announces Favorable Research Results
Myriad Genetics (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.…
Heres Why You Should Retain Myriad Genetics (MYGN) Stock Now
Investors are optimistic about Myriad Genetics (MYGN) strong solvency position and improvement in testing volume.…
[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…
Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay
Myriad Genetics (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to…
BioHive to launch HealthTech Hub Chapter to Empower Medical Innovation and Disrupt Healthcare
Salt Lake City, Utah, March 13, 2024 (GLOBE NEWSWIRE) -- BioHive, a nonprofit public-private partnership dedicated to enhancing…
Myriad Genetics (MYGN) to Evaluate MRD Testing With New Pact
Myriad Genetics (MYGN) MRD test is uniquely capable of detecting ctDNA at the lowest levels of detection, which is essential…
Myriad Genetics target raised to $28 on firm outlook By Investing.com
Myriad Genetics target raised to $28 on firm outlook…
Earnings call: Myriad Genetics reports positive 2023 results, eyes growth By Investing.com
Earnings call: Myriad Genetics reports positive 2023 results, eyes growth…
Myriad Genetics, Inc. (MYGN) Q4 2023 Earnings Call Transcript
…
Myriad Genetics (MYGN) Q4 Earnings Top Estimate, Margins Down
Myriad Genetics (MYGN) registers a strong testing volume improvement across all its businesses in the fourth quarter of 2023.…
Myriad Genetics, Inc. 2023 Q4 - Results - Earnings Call Presentation
…
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
Myriad’s Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types Myriad’s…
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
Myriads (MYGN) New Acquisition to Boost Precision Oncology Arm
Myriad Genetics (MYGN) is set to acquire certain assets of IPG, including Precise Liquid, which is expected to be launched…
Prenatal DNA Sequencing: Global Market Analysis Through 2018-2033 by Type, Application, End User and Region
Dublin, Jan. 19, 2024 (GLOBE NEWSWIRE) -- The "Prenatal DNA Sequencing Global Market Report 2024" report has been…
Myriad Genetics to acquire certain assets from Intermountain Precision Genomics
…
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
Heres Why You Should Retain Myriad Genetics (MYGN) Stock Now
Investors are optimistic about Myriad Genetics (MYGN) on robust testing volumes and strong solvency position.…
Myriad Genetics CFO Riggsbee retiring, Leffler named as successor
…
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance
SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
Myriad Genetics (MYGN) New Platform to Advance Cancer Care
Myriad Genetics (MYGN) new MCRR platform advances patient care by combining structured clinical data with genetic and genomic results.…
Myriad Genetics (MYGN) New Partnerships Aid Amid FX Woes
Myriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx…
Clinical Oncology Next Generation Sequencing Market Expected to Grow at a CAGR of 15.86% from 2023 to 2031
Companies covered in this report are Illumina Inc., Thermo Fisher Scientific, Agilent Technologies, F. Hoffmann-La Roche Ltd., Myriad Genetics, Perkin…
Heres Why You Should Retain Myriad Genetics (MYGN) Stock Now
Investors are optimistic about Myriad Genetics (MYGN) on recent partnerships and growth in testing volumes.…
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
SALT LAKE CITY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
Myriad Genetics (MYGN) Expands Pharma Services With New Pact
Myriad Genetics (MYGN) will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners with a new…
Myriad Genetics to Participate in Stephens Annual Investment Conference
SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…